SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.

Biotech SG&A Trends: Amicus vs. Iovance

__timestampAmicus Therapeutics, Inc.Iovance Biotherapeutics, Inc.
Wednesday, January 1, 2014207170009335772
Thursday, January 1, 20154726900012390000
Friday, January 1, 20167115100025602000
Sunday, January 1, 20178867100021262000
Monday, January 1, 201812720000028430000
Tuesday, January 1, 201916986100040849000
Wednesday, January 1, 202015640700060210000
Friday, January 1, 202119271000083664000
Saturday, January 1, 2022213041000104097000
Sunday, January 1, 2023275270000106916000
Loading chart...

Unleashing the power of data

SG&A Efficiency: A Tale of Two Biotechs

In the competitive world of biotechnology, managing operational costs is crucial. Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Amicus saw a staggering increase of over 1,200% in SG&A expenses, peaking at approximately $275 million in 2023. In contrast, Iovance's expenses grew by about 1,050%, reaching around $107 million in the same year. This divergence highlights Amicus's aggressive expansion strategy compared to Iovance's more conservative approach. Understanding these trends provides valuable insights into each company's operational focus and strategic priorities. As the biotech industry continues to evolve, monitoring such financial metrics will be key to predicting future market leaders.

Strategic Insights into Biotech Financials

Explore how two biotech giants manage their operational costs over time.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025